Relay Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Relay Therapeutics filed its Q2 2026 10-Q on 2026-08-06 for the period ended 2026-06-30. The filing header provides no substantive financial data, material contract changes, financing events, or strategic developments—only standard SEC document metadata and company registration information (incorporated in Delaware, headquartered at 60 Hampshire Street, Cambridge, MA).
Why this rating
Metadata-only filing excerpt; no financial statements, deal terms, or operational events disclosed here to assess materiality relative to $585.5M market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.